Pre-Diagnostic Circulating Resistin Concentrations Are Not Associated with Colorectal Cancer Risk in the European Prospective Investigation into Cancer and Nutrition Study
Metadatos
Mostrar el registro completo del ítemEditorial
MDPI
Materia
Pre-diagnostic resistin Colorectal cancer Risk Prospective Inflammation
Fecha
2022-11-09Referencia bibliográfica
Pham, T.-T... [et al.]. Pre-Diagnostic Circulating Resistin Concentrations Are Not Associated with Colorectal Cancer Risk in the European Prospective Investigation into Cancer and Nutrition Study. Cancers 2022, 14, 5499. [https://doi.org/10.3390/cancers14225499]
Patrocinador
World Health Organization; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London; Danish Cancer Society; Ligue contre le Cancer (France); Institut Gustave Roussy (France); Mutuelle Generale de l'Education Nationale (France); Institut National de la Sante et de la Recherche Medicale (Inserm); Deutsche Krebshilfe; Federal Ministry of Education & Research (BMBF); Hellenic Health Foundation (Greece); Fondazione AIRC per la ricerca sul cancro; Consiglio Nazionale delle Ricerche (CNR); Netherlands Government Netherlands Government; World Cancer Research Fund International (WCRF); Netherlands Government; Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway); Instituto de Salud Carlos III; Junta de Andalucia; Principality of Asturias; Regional Government of Basque Country (Spain); Regional Government of Murcia (Spain); Regional Government of Navarra (Spain); Instituto de Salud Carlos III RD06/0020; Swedish Cancer Society; Swedish Scientific Council (Sweden); Regional Government of Skane and Vasterbotten (Sweden); UK Research & Innovation (UKRI); Medical Research Council UK (MRC); Cancer Research UK; Netherlands Government; Deutsches Krebsforschungszentrum (Germany) ERC-2009-AdG 232997Resumen
Resistin is a polypeptide implicated in inflammatory processes, and as such could be
linked to colorectal carcinogenesis. In case-control studies, higher resistin levels have been found
in colorectal cancer (CRC) patients compared to healthy individuals. However, evidence for the
association between pre-diagnostic resistin and CRC risk is scarce. We investigated pre-diagnostic
resistin concentrations and CRC risk within the European Prospective Investigation into Cancer and
Nutrition using a nested case-control study among 1293 incident CRC-diagnosed cases and 1293
incidence density-matched controls. Conditional logistic regression models controlled for matching
factors (age, sex, study center, fasting status, and women-related factors in women) and potential
confounders (education, dietary and lifestyle factors, body mass index (BMI), BMI-adjusted waist
circumference residuals) were used to estimate relative risks (RRs) and 95% confidence intervals (CIs)
for CRC. Higher circulating resistin concentrations were not associated with CRC (RR per doubling
resistin, 1.11; 95% CI 0.94–1.30; p = 0.22). There were also no associations with CRC subgroups
defined by tumor subsite or sex. However, resistin was marginally associated with a higher CRC
risk among participants followed-up maximally two years, but not among those followed-up after
more than two years. We observed no substantial correlation between baseline circulating resistin
concentrations and adiposity measures (BMI, waist circumference), adipokines (adiponectin, leptin),
or metabolic and inflammatory biomarkers (C-reactive protein, C-peptide, high-density lipoprotein
cholesterol, reactive oxygen metabolites) among controls. In this large-scale prospective cohort, there
was little evidence of an association between baseline circulating resistin concentrations and CRC
risk in European men and women.